Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 14;14:4893. doi: 10.1038/s41467-023-40402-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — A Waterfall plot of the best response in platinum-resistant NPC patients. Best change in the sum of target lesion size compared with that at baseline (n = 36). The horizontal lineat −30 shows the threshold for defining an objective response in the absence of non-target disease progression or new lesions according to RECIST 11. One patient with 100% reduction in target lesion size had non-target lesions present. White stars, two patients had normalization (<10 mm) of fluor-8-deoxyglucose (FDG)-negative lymph nodes (at baseline, lymph nodes were >1.5 cm and FDG+) and 100% reduction of non-lymph node lesions and are considered to have had a CR (purple bar). B Spider plot of measurements of target lesions at each timepoint in platinum-resistant NPC patients (n = 36). C Swimmer plot (n = 36). D Kaplan–Meier curves for progression-free survival. E Response retention rate in platinum-resistant NPC patients. F Kaplan–Meier curves for overall survival.